– USA, MA – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced today the appointment of Bruce Peacock to its board of directors and audit committee. Mr. Peacock currently serves as chief financial and business officer at Ophthotech Corporation.
“Bruce Peacock is a recognized leader in the biotech industry,” stated the company’s chief executive officer, Dr. Douglas Fambrough. “With an impressive list of accomplishments in operations, management and business development, Bruce will be a terrific addition to our board.”
Mr. Peacock has been with Ophthotech Corporation since 2010 and previously served as the chief executive officer of Alba Therapeutics, The Little Clinic, Adolor Corp., and Orthovita Inc., and as chief operating officer of Cephalon Inc. and chief financial officer of Centocor Inc. Mr. Peacock also serves as co-chair of Alba Therapeutics, and as a member of the board of directors of Discovery Laboratories Inc., Ocular Therapeutix, and Invisible Sentinel Inc. Mr. Peacock holds a B.A. from Villanova University and is a certified public accountant.
“This is an especially exciting time for Dicerna,” stated Mr. Peacock. “I look forward to working with the Dicerna team in developing innovative treatments for genetically defined cancers and rare inherited diseases involving the liver.”
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.